0.07
-18.75%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Restart Life Sciences
Its shares trade on Canadian Securities Exchange under the ticker HEAL.CN. It has been listed since 22 September 2006. In the fiscal year to 31 December 2020, it reported revenue of C$11,500 and a net loss of C$25.2m. At that date it held total assets of C$3.0m and shareholders' equity of C$2.7m.
Nova Mentis Life Science Corp. is a biotechnology company, which engages in building and supporting a diversified portfolio of cannabis-sector businesses. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-09-22. The firm is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The firm has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The firm operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Sept 2006
- Website
- novamentis.ca ↗
Leadership
Pay as last reported
- Mr. Steve LoutskouChairman of the Board, President, Chief Executive Officer
- Ms. Rebecca HudsonChief Financial OfficerC$72,000
- Ms. Kelly PladsonCorporate Administrator
- Ms. Khavita HarrycharranDirector
- Dr. Georg HochwimmerDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nova Mentis Biotech Corp. has orphan drug designation in the US and EU for psilocybin treatment of fragile X syndrome.
- The company focuses on neuroinflammatory disorders with three categories: neurodevelopmental, neurometabolic, and neurodegenerative.
- Nova Mentis Life Science Corp. operates in Canada through wholly owned subsidiaries for R&D.
Weaknesses
- The firm's R&D is limited to psilocybin therapeutics without diversified product lines.
- Nova Mentis Biotech Corp. relies solely on Canada for geographic operations without international expansion.
- SwabAi Diagnostics Inc. is a single subsidiary focused on diagnostics without broader applications.
Opportunities
- Orphan drug designation in the US and EU supports psilocybin-based therapeutics for FXS and ASD.
- Growing focus on neuroinflammatory disorders presents market opportunities in chronic conditions.
- The company can expand its portfolio within the Canadian biotechnology sector.
Threats
- Psilocybin-based therapeutics face regulatory challenges in the cannabis sector.
- Fragile X syndrome treatment has limited market size compared to broader conditions.
- Dependence on a single therapeutic approach may limit growth potential.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.